Abstract
Psoriatic arthritis (PsA) is an inflammatory arthritis, characterized by mild arthralgia to severe joint deformities. Long term management of these diseases with nonsteroidal anti-inflammatory drugs (NSAIDs) and diseasemodifying antirheumatic drugs (DMARDs) is limited due to lack of efficacy and potential organ toxicity. Recently, the approval of injectable biologics, such as T cell inhibitors and TNF-α antagonist, has changed the treatment of moderateto- severe psoriasis and PsA. Unlike NSAIDs and DMARDs, TNF-α antagonists not only provide unambiguous benefits for the skin and joints, but also prevent the progression of structural damage in peripheral joints. Biological agents in the treatment of PsA have broad prospects. More and more biological agents are being developed for the treatment of PsA. In the current review, we will discuss the progress of biological agents on PsA.
Keywords: Biotherapy, psoriatic arthritis, T-cell modulating agents, TNF-α inhibitors.
Current Pharmaceutical Biotechnology
Title:Progress of Biological Agents on Psoriatic Arthritis
Volume: 15 Issue: 6
Author(s): Yan Li, Dashan Wang, Yantang Wang and Guixiu Shi
Affiliation:
Keywords: Biotherapy, psoriatic arthritis, T-cell modulating agents, TNF-α inhibitors.
Abstract: Psoriatic arthritis (PsA) is an inflammatory arthritis, characterized by mild arthralgia to severe joint deformities. Long term management of these diseases with nonsteroidal anti-inflammatory drugs (NSAIDs) and diseasemodifying antirheumatic drugs (DMARDs) is limited due to lack of efficacy and potential organ toxicity. Recently, the approval of injectable biologics, such as T cell inhibitors and TNF-α antagonist, has changed the treatment of moderateto- severe psoriasis and PsA. Unlike NSAIDs and DMARDs, TNF-α antagonists not only provide unambiguous benefits for the skin and joints, but also prevent the progression of structural damage in peripheral joints. Biological agents in the treatment of PsA have broad prospects. More and more biological agents are being developed for the treatment of PsA. In the current review, we will discuss the progress of biological agents on PsA.
Export Options
About this article
Cite this article as:
Li Yan, Wang Dashan, Wang Yantang and Shi Guixiu, Progress of Biological Agents on Psoriatic Arthritis, Current Pharmaceutical Biotechnology 2014; 15 (6) . https://dx.doi.org/10.2174/138920101506140910150227
DOI https://dx.doi.org/10.2174/138920101506140910150227 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
25th Anniversary Special Issue.
Current Pharmaceutical Biotechnology (CPB) is celebrating its 25th anniversary with a special issue highlighting the journal’s growth and its pivotal contributions to innovation and knowledge in academia. Since its inaugural issue in 2000, CPB has fostered a multidisciplinary platform for emerging scholars to publish high-quality research in pharmaceutical biotechnology. Over ...read more
Applications and Challenges of Nano-Biotechnology
This thematic issue aims to introduce readers to the fascinating intersection of nanotechnology and biology. It will bring together fundamental principles, materials, tools, and recent breakthroughs to help learners, researchers, and innovators understand how nanoscale science is revolutionizing biological and medical applications. Contributing authors will submit papers related to foundational ...read more
Latest Advancements in Biotherapeutics.
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
Machine Learning and Artificial Intelligence for Medical Data Analysis and Human Information Analysis in Healthcare
The intersection of machine learning (ML) and artificial intelligence (AI) with the pharmaceutical industry is revolutionizing traditional paradigms in drug discovery and development. These technologies have introduced innovative approaches to analyzing complex datasets and predicting chemical properties, leading to more efficient identification and optimization of drug candidates. By employing sophisticated ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Disproportionality Analysis of Pharmacovigilance Databases in Safety Regulatory Actions: a Systematic Review
Current Drug Safety Endotherapia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Monoclonal Antibody “Gold Rush”
Current Medicinal Chemistry The Multiple Aspects of Stroke and Stem Cell Therapy
Current Molecular Medicine Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins
Current Drug Targets Financial Returns on R&D: Looking Back at History, Looking Forward to Adaptive Licensing
Reviews on Recent Clinical Trials HIV-1-Associated Dementia During HAART Therapy
Recent Patents on CNS Drug Discovery (Discontinued) Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Vascular Pharmacotherapy and Dementia
Current Vascular Pharmacology Pharmacotherapy and Prevention of Vascular Dementia
CNS & Neurological Disorders - Drug Targets The Cytokine Network in HIV Infection
Current Molecular Medicine Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment
Current Cancer Therapy Reviews Hsp70 Molecular Chaperones: Emerging Roles in Human Disease and Identification of Small Molecule Modulators
Current Topics in Medicinal Chemistry Neuroimaging Features of Acquired Metabolic and Toxic Encephalopathies
Current Medical Imaging Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews Monoclonal Antibodies in the Treatment of Neuroimmunological Diseases
Current Pharmaceutical Design Silencing the Brain May be Better than Stimulating it. The GABA Effect
Current Pharmaceutical Design Survey of Latin American Neuroimmunologists on the Treatment of Multiple Sclerosis with Monoclonal Antibodies
Current Drug Safety Targeting Notch as a Therapeutic Approach for Human Malignancies
Current Pharmaceutical Design Treatment of Leukoaraiosis: A Futuristic View
Current Drug Targets